
June 9 (Reuters) - Ascendis Pharma A/S A71.F:
TRANSCON® HGH BOOSTED TREATMENT BENEFITS OF TRANSCON® CNP IN CHILDREN WITH ACHONDROPLASIA AT WEEK 26 INTERIM ANALYSIS OF THE PHASE 2 COACH TRIAL
ASCENDIS PHARMA A/S - TRANSCON CNP-TREATED COHORT SHOWS 8.25 CM/YEAR AGV
ASCENDIS PHARMA A/S - COMBINATION TREATMENT SHOWS IMPROVED BODY PROPORTIONALITY AT WEEK 26
ASCENDIS PHARMA A/S -SAFETY AND TOLERABILITY DATA CONSISTENT WITH THOSE OBSERVED FOR TRANSCON HGH AND TRANSCON CNP MONOTHERAPIES